Departments of *Obstetrics and Gynecology †Radiation Oncology ‡Preventive Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
Am J Clin Oncol. 2014 Feb;37(1):30-4. doi: 10.1097/COC.0b013e31826103d0.
We reviewed data on treatment of stage IB1 cervical cancer at our institution to compare recurrence, complications, and survival of women treated primarily by radical hysterectomy versus radiation.
Records for women treated for stage IB1 cervical cancer between January 1, 1990 and June 1, 2010 were retrospectively reviewed. Recurrence, survival outcomes, and complications were examined and compared. Demographic, clinical, and histopathologic factors were also analyzed.
Of 198 patients with stage IB1 cervix cancer, 169 (85%) underwent radical hysterectomy, including 37 (20%) who received postoperative radiation, and 29 (15%) were treated primarily with radiotherapy±chemotherapy. Progression-free survival, overall survival, and disease-specific survival were all longer in the surgery group (89%, 95%, and 96%) versus the radiation group (70%, 70%, and 78%), respectively (P<0.001). Patients in the radiation group were older, had larger tumors, and were more likely to have medical comorbidities than patients in the surgery group. Within the surgical cohort, lymphvascular space invasion, outer third cervical stromal invasion, positive surgical margins, and lymph node metastasis were all predictive of recurrence (P<0.002), whereas histopathology, smoking, diabetes, and immunosuppression were not. Grade 3 or 4 complication rates were higher among the 29 patients who had primary radiotherapy (20.7%) and the 37 patients who had surgery followed by radiotherapy (21.6%) compared with the 132 patients who had surgery only (9.1%) (P=0.047).
Primary treatment of stage IB1 cervix cancer with radical hysterectomy±adjuvant radiation resulted in a significantly lower rate of recurrence and an improved survival with fewer complications compared with radiotherapy with or without chemotherapy.
我们回顾了我院治疗 IB1 期宫颈癌的数据,以比较根治性子宫切除术与放疗治疗该病的复发率、并发症和生存率。
回顾了 1990 年 1 月 1 日至 2010 年 6 月 1 日期间治疗 IB1 期宫颈癌的女性患者的病历。检查并比较了复发、生存结果和并发症。还分析了人口统计学、临床和组织病理学因素。
在 198 例 IB1 期宫颈癌患者中,169 例(85%)接受了根治性子宫切除术,其中 37 例(20%)接受了术后放疗,29 例(15%)主要接受了放化疗。无进展生存率、总生存率和疾病特异性生存率在手术组(分别为 89%、95%和 96%)均长于放疗组(分别为 70%、70%和 78%)(P<0.001)。与手术组相比,放疗组患者年龄更大,肿瘤更大,且更易合并内科疾病。在手术组中,淋巴血管间隙浸润、宫颈外三分之一间质浸润、手术切缘阳性和淋巴结转移均为复发的预测因素(P<0.002),而组织病理学、吸烟、糖尿病和免疫抑制不是。单纯放疗的 29 例患者(20.7%)和根治性子宫切除术加术后放疗的 37 例患者(21.6%)的 3 级或 4 级并发症发生率高于单纯手术的 132 例患者(9.1%)(P=0.047)。
与单纯放化疗相比,根治性子宫切除术加辅助放疗治疗 IB1 期宫颈癌的复发率显著降低,生存率提高,并发症减少。